Population pharmacokinetic model for topotecan derived from phase I clinical trials

Journal of Clinical Oncology

Volumn 18, Issue 12, 2000, Pages 2459-2467

  Gallo, James M ^a   Laub, Paul B ^a   Rowinsky, Eric K ^a   Grochow, Louise B ^a   Baker, Sharyn D ^a  

^a CTRC Institute for Drug Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; TOPOTECAN;

ADULT; AGED; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COMPARTMENT MODEL; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; FEMALE; HUMAN; KIDNEY FAILURE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0034086522     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.12.2459     Document Type: Article

References (33)

1. Herben VMM, Huinink WWtB, Beijnen JH: Clinical pharmacokinetics of topotecan. Clin Pharmacokinet 31:85-102, 1996
2. Grochow LB, Rowinsky EK, Johnson R, et al: Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Drug Metab Dispos 20:706-713, 1992
3. Haas NB, LaCreta FP, Walczak J, et al: Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly. Cancer Res 54:1220-1226, 1994
4. Herben VM, ten Bokkel Huinink WW, Schot ME, et al: Continuous infusion of low-dose topotecan: Pharmacokinetics and pharmacodynamics during a phase II study in patients with small cell lung cancer. Anticancer Drugs 9:411-418, 1998
5. O'Reilly S, Rowinsky E, Slichenmyer W, et al: Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function. J Natl Cancer Inst 88:817-24, 1996
6. O'Reilly S, Rowinsky EK, Slichenmyer W, et al: Phase I pharmacological study of topotecan in patients with impaired renal function. J Clin Oncol 14:3062-3073, 1996
7. Rowinsky EK, Grochow LB, Hendricks CB, et al: Phase I and pharmacological study of topotecan: A novel topoisomerase I inhibitor. J Clin Oncol 10:647-656, 1992
8. Rowinsky EK, Adjei A, Donehower RC, et al: Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. J Clin Oncol 12:2193-2203, 1994
9. Dennis MJ, Beijnen JH, Grochow LB, et al: An overview of the clinical pharmacology of topotecan. Semin Oncol 24:S5-18, 1997 (suppl 5)
10. van Warmerdam LJC, Verweij J, Schellens JHM, et al: Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks. Cancer Chemother Pharmacol 35:237-245, 1995
11. Chatelut E, Canal P, Brunner V, et al: Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 87:573-580, 1995
12. Chatelut E, Boddy AV, Peng B, et al: Population pharmacokinetics of carboplatin in children. Clin Pharmacol Ther 59:436-443, 1996
13. Bruno R, Vivier N, Vergniol JC, et al: A population pharmacokinetic model for docetaxel (Taxotere): Model building and validation. J Pharmacokinet Biopharm 24:153-172, 1996
14. Rowinsky EK, Kaufmann SH, Baker SD, et al: Sequences of topotecan and cisplatin: Phase I, pharmacological, and in vitro studies to examine sequence dependence. J Clin Oncol 14:3074-3084, 1996
15. Rowinsky EK, Grochow LB, Sartorius SE, et al: Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors. J Clin Oncol 14:1224-35, 1996
16. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41, 1976
17. Beijnen JH, Smith BR, Keijer WJ, et al: High performance liquid chromatographic analysis of the new antitumor drug SK&B 10464-A (NSC 606699) in plasma. J Pharm Biomed Anal 8:789-794, 1990
18. Mandema JW, Verotta D, Sheiner LB: Building population pharmacokinetic-pharmacodynamic models, in D'Argenio DZ (ed): Advanced Methods of Pharmacokinetic and Pharmacodynamic Systems Analysis (vol 2). New York, NY, Plenum Press, 1995, pp 69-86
19. Beal SL, Boeckman, Sheiner LB: NONMEM: User's Guide Part I-VIII. San Francisco, CA, University of California at San Francisco, 1998
20. Jonsson N, Karlsson M: Xpose 2.0 User's Manual. Uppsala, Sweden, Uppsala University, November 1998
21. S-Plus (version 4.5). Seattle, WA, MathSoft, Inc, 1997
22. JMP (version 3.2.2). Cary, NC, SAS Institute, Inc, 1997
23. Akaike H: An information criterion. Math Sci 14:5-9, 1976
24. Hastie TJ, Tibshirani RJ: Generalized Additive Models. London, England, Chapman & Hall, 1990, pp 256-259
25. Sheiner LB, Beal SL: Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9:503-512, 1981
26. Holford NHG, Sheiner LB: Pharmacokinetic and pharmacodynamic modeling in vivo. CRC Crit Rev Bioeng 5:273-322, 1981
27. Bruno R, Hille D, Riva A, et al: Population pharmacokinetics/ pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 16:187-196, 1998
28. Mi Z, Malak H, Burke TG: Reduced albumin binding promotes the stability and activity of topotecan in human blood. Biochem 34:13722-13728, 1995
29. Levey AS, Bosch JP, Lewis JB: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 130:461-470, 1999
30. George SL, Gehan EA: Methods for measurement of body surface area. J Pediatr 94:342-343, 1979 (letter)
31. Karlsson MO, Port RE, Ratain MJ, et al: A population model for the leukopenic effect of etoposide. Clin Pharmacol Ther 57:325-334, 1995
32. Gallo JM, Brennan J, Halbherr T, et al: Time-dependent pharmacodynamic models in cancer chemotherapy: Population pharmacodynamic model for glutathione depletion following administration of buthionine sulfoximine (BSO) in a phase I trial of melphalan and BSO. Cancer Res 55:4507-4511, 1995
33. Vozeh S: Applications of population approach to clinical pharmacokinetics and validation of the results, in Rowland M, Aarons L (eds): New Strategies in Drug Development and Clinical Evaluation: The Populalion Approach. Luxembourg City, Luxembourg, Commission of the European Communities, 1992, pp 107-120